ProCE Banner Activity

Interactive Decision Support Tool: HER2-Positive Metastatic Breast Cancer Expert Guidance

Tool

Use this Interactive Decision Support Tool to compare your choice of therapy for patients with HER2+ MBC with those of 5 renowned experts.

Released: November 23, 2022

Expiration: November 22, 2023

No longer available for credit.

Share

Faculty

Aditya Bardia

Aditya Bardia, MD, MPH, FASCO

Professor of Medicine
Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research)
Division of Medical Oncology
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, California

Sara A. Hurvitz

Sara A. Hurvitz, MD

Professor of Medicine
Director
Breast Cancer Clinical Trials Program
Division of Hematology/Oncology
David Geffen School of Medicine
Medical Director
Clinical Research Unit
Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Los Angeles, California

Komal Jhaveri

Komal Jhaveri, MD, FACP

Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Heather McArthur

Heather McArthur, MD, MPH

Associate Professor
Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

Sara M. Tolaney

Sara M. Tolaney, MD, MPH

Assistant Professor of Medicine
Harvard Medical School
Associate Director
Susan F. Smith Center for Women’s Cancers
Director
Clinical Trials, Breast Oncology
Director
Breast Immunotherapy Clinical Research
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Puma Biotechnology, Inc.

Seagen Inc.

Partners

Smart Patients

ProCE Banner

Faculty Disclosure

Contributing Author

Aditya Bardia, MD, MPH, FASCO

Professor of Medicine
Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research)
Division of Medical Oncology
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, California

Aditya Bardia, MD, MPH, FASCO: consultant/advisor/speaker: Daiichi Sankyo/AstraZeneca, Genentech, Gilead, Lilly, Menarini, Merck, Novartis, Pfizer, Sanofi; researcher: Daiichi Sankyo/AstraZeneca, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, Sanofi.

Sara A. Hurvitz, MD

Professor of Medicine
Director
Breast Cancer Clinical Trials Program
Division of Hematology/Oncology
David Geffen School of Medicine
Medical Director
Clinical Research Unit
Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Los Angeles, California

Sara Hurvitz, MD, FACP: researcher: Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, Cytomx, Daiichi-Sankyo, Dantari, Dignitana, Genentech/Roche, G1 Therapeutics, Gilead, GlaxoSmithKline, Greenwich Life Sciences, Immunomedics, Lilly, Macrogenics, Novartis, OBI Pharma, Orinove, Orum, Pfizer, Phoenix Molecular Designs, Pieris, PUMA, Radius, Samumed, Sanofi, Seattle genetics/Seagen, Zymeworks.

Komal Jhaveri, MD, FACP

Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Komal Jhaveri, MD, FACP: consultant/advisor/speaker: AbbVie, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Genentech/Roche, Jounce Therapeutics, Lilly/Loxo Oncology, Menarini/stemline, Novartis, Pfizer, Scorpion Therapeutics, Seattle Genetics, Sun Pharma Advanced Research Company Ltd, Taiho Oncology; researcher (paid to institution): ADC Therapeutics, AstraZeneca, Blueprint Medicine, Debio Pharmaceuticals, Genentech, Gilead, Lilly, Merck, Novartis, Novita Pharmaceuticals, Pfizer, PUMA Biotechnology, Scorpion Therapeutics, Zymeworks.

Heather McArthur, MD, MPH

Associate Professor
Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

Heather McArthur, MD, MPH: consultant/advisor/speaker: AstraZeneca, Daiichi-Sankyo, Merck, Moderna, Pfizer.

Sara M. Tolaney, MD, MPH

Assistant Professor of Medicine
Harvard Medical School
Associate Director
Susan F. Smith Center for Women’s Cancers
Director
Clinical Trials, Breast Oncology
Director
Breast Immunotherapy Clinical Research
Dana-Farber Cancer Institute
Boston, Massachusetts

Sara Tolaney, MD, MPH: consultant/advisor: 4D Pharma, Aadi Biopharma, ARC Therapeutics, Artios Pharma, AstraZeneca, Bayer, BeyondSpring Pharmaceuticals, Blueprint Medicines, Bristol Myers Squibb, CytomX Therapeutics, Daiichi Sankyo, Eisai, Ellipses Pharma, Genentech/Roche, Gilead, Incyte Corp, Infinity Therapeutics, Jazz Pharmaceuticals, Lilly, Menarini/Stemline, Merck, Myovant, Novartis, OncoSec Medical Inc., OncXerna, Pfizer, Reveal Genomics, Sanofi, Seattle Genetics, Umoja Biopharma, Zentalis, Zetagen, Zymeworks; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Gilead, Gilead, Lilly, Merck, NanoString Technologies, Novartis, OncoPep, Pfizer, Seattle Genetics.